Cure8 research brief
This review suggests a new way to think about IBD relapse and disease persistence: persistent changes in innate immune cells (trained immunity) could maintain gut inflammation even when adaptive immune targets are controlled.
If confirmed, this could open paths to biomarkers or treatments addressing innate immune memory.
Researchers, clinicians, and informed patients interested in IBD pathogenesis, biomarkers, and novel therapeutic strategies.
This is a narrative review proposing that trained immunity — long-lived functional changes in innate immune cells driven by metabolic and epigenetic reprogramming after infections or inflammatory exposures — could contribute to IBD persistence and relapse.
The authors summarize preclinical evidence that monocytes, macrophages, and their bone marrow progenitors can acquire a sustained proinflammatory “memory” after exposure to microbial ligands, dysbiotic metabolites, or metabolic stressors in the gut.
The review highlights translational implications: trained immunity might help explain relapse during clinical remission, and could point to new biomarker strategies, patient stratification approaches, or therapies that target innate immune reprogramming rather than only adaptive immunity.
This article is framed as an overview of current insights and hypotheses rather than reporting new clinical trial data. It discusses mechanisms and potential directions for future research.
Narrative review grounded in preclinical and mechanistic literature; does not provide clinical trial evidence. Findings are hypothesis-generating and need validation in human studies.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This paper highlights potential ubiquitination-related genes and immune-cell patterns that could help researchers understand Crohn’s disease biology and point to new targets for lab validation. For patients, it signals...
A biomarker that appears before inflammation could help detect Crohn’s disease earlier or predict relapses. Understanding early immune changes may point to new preventive strategies rather than only treating inflammation...
The findings point to an immune-cell change that may happen before Crohn’s symptoms appear, which could help predict relapse or guide future therapies. That could eventually affect monitoring or new treatment strategies...
